Biogen Inc. (BIIB)
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark
Biogen's Q2 earnings show flat revenue growth but a 31% increase in non-GAAP EPS. The focus is on Alzheimer's drug Leqembi as potential revenue driver, now it has secured full FDA approval and is generating positive longer-term clinical data. Biogen's pipeline includes potential revenue contributors in Alzheimer's, Parkinson's, and kidney disease therapies, pain therapeutics and MS.
Prediction: The Next Big Biotech Stock Boom Will Be in Longevity Drugs
Treating aging and its consequences will be a colossal market. The first seeds of the coming boom have already been planted.
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
A blood test that checks for an abnormal protein could detect 90% of Alzheimer's cases. Eli Lilly recently obtained approval for an early Alzheimer's treatment, Kisunla.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Biogen Inc. (BIIB) Q2 2024 Earnings Call Transcript
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $4 per share. This compares to earnings of $4.02 per share a year ago.
Drug maker Biogen boosts profit outlook and tops Q2 profit estimate
Biogen Inc.'s stock BIIB rose 1.8% in premarket trading on Thursday after the drug aker boosted its outlook for its adjusted 2024 profit and topped Wall Street's second-quarter profit expectations. The company cited “positive momentum across new product launches such as its Leqembi Alzheimer's medicine, which rang up $40 million in sales in the quarter.
Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
Biogen reported second-quarter earnings and revenye that topped estimates and hiked its full-year guidance as cost-cutting efforts showed progress and sales of its breakthrough Alzheimer's drug, Leqembi, and other new products came in higher than expected. The biotech company is pinning its hopes on Leqembi and other new products to drive growth as it reduces costs and grapples with declining demand for its multiple sclerosis therapies.
